Compare FTFT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | NCNA |
|---|---|---|
| Founded | N/A | 1997 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 5.7M |
| IPO Year | 2008 | 2017 |
| Metric | FTFT | NCNA |
|---|---|---|
| Price | $1.62 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 170.6K | 67.2K |
| Earning Date | 05-19-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,829,805.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.46 | N/A |
| 52 Week Low | $0.45 | $1.21 |
| 52 Week High | $3.88 | $7.01 |
| Indicator | FTFT | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.35 | 46.27 |
| Support Level | $0.98 | $1.21 |
| Resistance Level | $1.70 | $2.27 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 65.66 | 13.96 |
Future FinTech Group Inc is engaged in the production and sale of fruit juice concentrates (including fruit purees and fruit juices), fruit beverages (including fruit juice beverages and fruit cider beverages) in the PRC. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The Company classified its business segments into Trading Commission and Consulting services, Fast-Moving Consumer Goods (FMCG), and Supply Chain Financing and Trading.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.